nanoMesh ™ LLC (a subsidiary of Exogenese Corporation) and Veteran’s Healthcare Supply Solutions (VHSS) announce national distribution agreement for the nanoMesh ™ product line available to the clinical community
BILLERICA, Mass. and JACKSONVILLE, Florida, August 3, 2021 / PRNewswire / – nanoMesh ™ LLC, a subsidiary of Exogenesis Corporation, and Veteran’s Healthcare Supply Solutions (VHSS) Announce National Distribution Agreement to Offer the nanoMesh ™ Line of Products to the Clinical Community. nanoMesh ™ is indicated for the repair of abdominal wall hernias and abdominal wall deficiencies which require the addition of reinforcing material to achieve the desired surgical result. nanoMesh ™ is commercially available in the United States. nanoMesh ™ has a unique surface texture at the nanometer level, through the application of Accelerated Neutral Atom Beam (ANAB) technology during manufacture.
For inquiries about nanoMesh ™ products, please visit: [https://exogenesisnanomesh.com]
Gary Skura, CEO of VHSS commented, “nanoMesh ™ is a great addition to the VHSS portfolio.” NanoMesh ™ is a technology adjacent to our expanding surgical portfolio and we are delighted to help them build this brand. We are pleased that nanoMesh ™ has recognized our dedication and passion for providing these innovative products to the clinical medical device community.
Previously reported exogenesis July 6, 2021, Extension of the range of nanoMesh ™ products to the clinical community
Previously reported exogenesis June 9, 2021, secondary endpoint met in nanoMesh ™ Pathogen Inhibiting Protein (PIP) uptake studies
Previously reported exogenesis June 1, 2021, primary endpoint achieved in nanoMesh ™ Pathogen Inhibiting Protein (PIP) uptake studies
Previously reported exogenesis April 21, 2021, nanoMesh ™ LLC (a subsidiary of Exogenesis Corporation) has completed the first human clinical implantation of nanoMesh ™.
Exogenesis previously reported on April 6, 2021, Completed the US Food and Drug Administration (FDA) Second Pre-Market Notification (510 (k)) filing for nanoMesh ™.
Exogenesis previously reported on January 26, 2021, the completion of production validation and sterilization validation as an immediate prelude to commercialization of nanoMesh ™.
About nanoMesh ™
Exogenesis Hernia Mesh (“nanoMesh ™”) is a proprietary hernia repair product developed and marketed by nanoMesh ™ LLC. Constructed of monofilament polypropylene (PP) and surface treated with Accelerated Neutral Atom Beam (ANAB) technology, nanoMesh ™ is the first hernia repair device on the market with nano-surface modification. nanoMesh ™ is indicated for the repair of abdominal wall hernia defects, including inguinal (direct and indirect). nanoMesh ™ is not indicated for the transvaginal repair of pelvic organ prolapse.
About Accelerated Neutral Atom Beam (“ANAB”) Technology
The Accelerated Neutral Atom Beam (“ANAB”) is a low energy accelerated particle beam that is marketed as a nanoscale surface modification technology. ANAB is created by the acceleration of very low energy neutral argon (Ar) atoms in a vacuum which bombard the surface of a material, altering it to a shallow depth of 2-3 nm. It is a non-additive technology that causes changes in the topography, structure and energy of the surface. Medical implants treated with ANAB technology recently received FDA 510 (k) regulatory clearance for use in spinal interbody fusion (IBD) devices.
About Hernia Repair Market
The Global Hernia Repair Market should reach $ 5.8 billion by 2026. Hernias often occur in the abdominal wall and are usually visible as an external bulge, especially during exertion or pushing. It affects people to a large extent causing significant pain and discomfort. Age, pregnancy, obesity, muscle tension and surgery increase the risk of a hernia. Surgical nets of various constructions have been used since the end of the 19e century. In recent years, research in the field has increased due to the increasing number of post-operative complications such as infection, fibrosis, adhesions, mesh rejection and hernia recurrence. Research has focused on the analysis and implementation of a wide range of materials and coatings, meshes with different fiber thicknesses and porosities, a variety of manufacturing methods, as well as surgical procedures and d implantation. More recently, surface modification methods, as well as the development of nanofiber-based systems, are actively explored as promising avenues to increase the biocompatibility of available meshes.
About Veteran’s Healthcare Supply Solutions
VHSS offices and the 31,000 square foot distribution center are located Jacksonville, Florida. Since its inception in 2010, VHSS has grown into one of the largest SDVOSBs focused on healthcare distribution. VHSS is classified by the government as a Small Business Owned by a Disabled Veteran (SDVOSB). VHSS has a veteran-preferred workforce, with 13 of the current 19 employees having served. VHSS has been recognized with several awards of excellence: Top 50 – Service Disabled Veteran Owned Small Business, Small Cap Award 2016 for Best Veteran-Owned Medical Device Distributor in the United States, Best Small Business Medical Device Distributor in the United States. United States. Jacksonville for 2016, 2017, 2018 and 2019, and were inducted into the Jacksonville Small Business Hall of Fame. VHSS has trade agreements with all major suppliers for the VA (Cardinal, Concordance and Medline) and with the two major suppliers for the Department of Defense (Cardinal and Owens & Minor). VHSS contract portfolio includes Federal Procurement Schedule, Equipment ECAT (Electronic Catalog) and Medical / Surgical DAPA Agreement through Defense Logistics Agency, Non-Durable Equipment Contracts from VA’s Strategic Acquisition Center, products to VA’s primary medical / surgical supplier. Next Generation Program (MSPV-NG) and various individual customer contracts.
Based at Billerica, Massachusetts, USA, Exogenesis is a private, venture-funded company that has developed proprietary technology to modify and control surfaces without coating or creating damage below the surface. Exogenesis markets a platform technology, NanoAccel ™, using Accelerated Neutral Atom Beam (ANAB) and Gas Cluster Ion Beam (GCIB) technologies that modify and control the surfaces of materials at the nanoscale. The company’s proprietary technologies are used for surface modification and control in a wide range of biomedical, optical and semiconductor applications. For more information, please visit www.exogenesenanomesh.com or contact us at [email protected]
 Exogenesis Hernia Mesh has received 510 (k) pre-market clearance from the FDA September 26, 2019
 Protected by issued and pending patents.
 “Past, present and future of surgical nets: a review” – Membranes (Basel). September 2017; 7 (3): 47.
SOURCE nanoMesh LLC